RAPID AND SUSTAINED ACHIEVEMENT OF UNDETECTABLE HCV RNA DURING TREATMENT WITH RITONAVIR-BOOSTED DANOPREVIR/PEG-IFNα-2A/RBV IN HCV GENOTYPE 1 OR 4 PATIENTS: DAUPHINE WEEK 12 INTERIM ANALYSIS

被引：12
|
作者：
Everson, G. [1 ]
Cooper, C. [2 ]
Hezode, C. [3 ]
Shiffman, M. L. [4 ,5 ]
Yoshida, E. [6 ]
Beltran-Jaramillo, T. [7 ]
Ferenci, P. [8 ]
Zeuzem, S. [9 ]
Brunda, M. [10 ]
Shulman, N. [11 ]
Navarro, M. [11 ]
Voulgari, A. [12 ]
Najera, I. [10 ]
Le Pogam, S. [10 ]
Yetzer, E. S. [11 ]
机构：
[1] Univ Colorado, Sch Med, Denver, CO USA
[2] Ottawa Hosp, Div Infect Dis, Ottawa, ON, Canada
[3] Univ Paris 12, Hop Henri Mondor, F-94010 Creteil, France
[4] Bon Secours Hlth Syst, Liver Inst Virginia, Richmond, VA USA
[5] Bon Secours Hlth Syst, Liver Inst Virginia, Newport News, VA USA
[6] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[7] Asesor Dept Inmunoanalisis, Mexico City, DF, Mexico
[8] Med Univ Vienna, Vienna, Austria
[9] JW Goethe Univ Hosp, Frankfurt, Germany
[10] Roche, Nutley, NJ USA
[11] Genentech Inc, San Francisco, CA 94080 USA
[12] Roche, Welwyn Garden City, England
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)61189-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1177
引用
收藏
页码：S466 / S466
页数：1
相关论文
共 37 条
  • [1] High SVR24 rates with ritonavir-boosted danoprevir plus Peg-IFNα-2a ( 40KD)/RBV in HCV genotype 1 or 4 patients in the DAUPHINE study
    Everson, Gregory T.
    Cooper, Curtis
    Hezode, Christophe
    Shiffman, Mitchell L.
    Yoshida, Eric M.
    Beltran-Jaramillo, Teresita
    Andreone, Pietro
    Bruno, Savino
    Ferenci, Peter
    Zeuzem, Stefan
    Brunda, Michael
    Shulman, Nancy
    Le Pogam, Sophie
    Najera, Isabel
    Chi, Belinda
    Navarro, Mercidita T.
    Voulgari, Athina
    Yetzer, Ellen S.
    HEPATOLOGY, 2012, 56 : 552A - 552A
  • [2] LOW RATE OF ON-TREATMENT RESISTANCE TO DANOPREVIR BOOSTED BY RITONAVIR (DNVR) COMBINED WITH PEG-IFNα-2A/RIBAVIRIN: 12 WEEK INTERIM ANALYSIS FROM DAUPHINE STUDY
    Le Pogam, S.
    Navarro, M.
    Bu, L.
    Voulgari, A.
    Illnicka, M.
    Yan, J. M.
    Klumpp, K.
    Najera, I.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S472 - S472
  • [3] Ritonavir-boosted danoprevir plus Peg-IFNα-2a/ribavirin (P/R) demonstrates up to 100% SVR24 with 12 or 24 weeks of total treatment in treatment-naive patients with HCV genotype 4 infection in the DAUPHINE study
    Hezode, Christophe
    Shiffman, Mitchell L.
    Cooper, Curtis
    Everson, Gregory T.
    Marcellin, Patrick
    Rodriguez-Torres, Maribel
    Bourliere, Marc
    Pol, Stanislas
    Richardson, Denise
    Navarro, Mercidita T.
    Voulgari, Athina
    Shulman, Nancy
    Yetzer, Ellen S.
    HEPATOLOGY, 2012, 56 : 557A - 557A
  • [4] SUSTAINED VIROLOGICAL RESPONSE AFTER 4-WEEK TREATMENT WITH DEBIO 025 MONOTHERAPY OR COADMINISTERED WITH PEG-IFNα2A IN HCV GENOTYPE 1 AND 3 PATIENTS
    Horban, A.
    Berak, H.
    Kolakowska-Rzadzka, A.
    Patel, H.
    Flisiak, R.
    Crabbe, R.
    Liz, J. S.
    Heathcote, J. E.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S294 - S294
  • [5] Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study
    Kao, Jia-Horng
    Yu, Min-Lung
    Chen, Chi-Yi
    Peng, Cheng-Yuan
    Chen, Ming-Yao
    Tang, Huoling
    Chen, Qiaoqiao
    Wu, Jinzi J.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (08) : 1507 - 1510
  • [6] Overall low rate of resistance to danoprevir (DNV) in HCV genotype (G) 1/4 patients treated with ritonavir-boosted danoprevir (DNVr) plus peginterferon alfa-2a (40KD)/ribavirin (P/R) in the DAUPHINE study
    Le Pogam, Sophie
    Navarro, Mercidita T.
    Chi, Belinda
    Voulgari, Athina
    Klumpp, Klaus
    Najera, Isabel
    HEPATOLOGY, 2012, 56 : 571A - 572A
  • [7] EFFICACY AND SAFETY OF MERICITABINE (MCB) IN COMBINATION WITH PEG-IFNα-2A/RBV IN G1/4 TREATMENT NAIVE HCV PATIENTS: FINAL ANALYSIS FROM THE PROPEL STUDY
    Wedemeyer, H.
    Jensen, D.
    Herring, R., Jr.
    Ferenci, P.
    Ma, M. M.
    Zeuzem, S.
    Rodriguez-Torres, M.
    Bzowej, N.
    Pockros, P.
    Vierling, J.
    Ipe, D.
    Najera, I.
    Thommes, J.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S481 - S482
  • [8] PREMATURE TREATMENT DISCONTINUATION OF PEG-IFNα-2A/RBV DUE TO GOOD VIRAL RESPONSES AND INSUFFICIENT VIRAL RESPONSES AMONG HCV GENOTYPE 1, 2 AND 3 PATIENTS FROM PROPHESYS
    Mangia, A.
    Banyai, T.
    De Bartolomeo, G.
    Habersetzer, F.
    Mulkay, J. -P.
    Ouzan, D.
    Parruti, G.
    Passariello, N.
    Gervain, J.
    Remy, A. -J.
    Rizzetto, M.
    Shiffman, M. L.
    Tice, A. D.
    Schmitz, M.
    Tatsch, F.
    Rodriguez-Torres, M.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S447 - S448
  • [9] Week 8 HCV-RNA Is the Optimal Predictor of Relapse in non-RVR Patients with Genotype 1/4 Randomized to 48 or 72 Weeks PEG-IFN Alfa-2a Plus RBV
    Ferenci, Peter
    Scherzer, Thomas-Matthias
    Kerschner, Heidrun
    Beinhardt, Sandra
    Rutter, Karoline
    Hofer, Harald
    Steindl-Munda, Petra
    Popow-Kraupp, Theresia
    GASTROENTEROLOGY, 2009, 136 (05) : A843 - A843
  • [10] WEEK 8 HCV-RNA IS THE OPTIMAL PREDICTOR OF RELAPSE IN NON-RVR PATIENTS WITH GENOTYPE 1/4 RANDOMISED TO 48 OR 72 WEEKS PEG-IFN ALFA-2A PLUS RBV
    Scherzer, T. -M.
    Kerschner, H.
    Beinhardt, S.
    Rutter, K.
    Hofer, H.
    Steindl-Munda, P.
    Popow-Kraupp, T.
    Ferenci, P.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S225 - S225
1234